Liver resection for hepatocellular carcinoma larger than 10 cm: A multi-institution long-term observational study

Table 6 Analyses of survival outcome with and without inverse-probability of treatment weighting between the two groups (hepatectomy vs transarterial chemoembolization) - TNM and Barcelona Clinic Liver Cancer stage

	Without IPTW				With IPTW
	Unadjusted		Adjusted		Unadjusted		Adjusted
	Hazard ratio (95%CI)	P value	Hazard ratio (95%CI)	P value	Hazard ratio (95%CI)	P value	Hazard ratio (95%CI)	P value
All-cause mortality
Entire cohort	0.33 (0.28-0.40)	< 0.001	0.46 (0.38-0.55)	< 0.001	0.49 (0.39-0.61)	< 0.001	0.46 (0.38-0.56)	< 0.001
Within stage I					0.39 (0.20-0.80)	0.009	0.37 (0.19-0.73)	0.004
Within stage II					0.30 (0.16-0.54)	< 0.001	0.24 (0.13-0.45)	< 0.001
Within stage III					0.50 (0.41-0.62)	< 0.001	0.50 (0.40-0.62)	< 0.001
Within stage IV					0.31 (0.14-0.67)	0.003	0.30 (0.09-0.93)	0.037
Liver-cause mortality
Entire cohort	0.32 (0.26-0.39)	< 0.001	0.45 (0.37-0.56)	< 0.001	0.48 (0.37-0.61)	< 0.001	0.46 (0.37-0.56)	< 0.001
Within stage I					0.33 (0.16-0.71)	0.004	0.27 (0.12-0.60)	0.001
Within stage II					0.30 (0.16-0.56)	< 0.001	0.22 (0.10-0.47)	< 0.001
Within stage III					0.50 (0.39-0.63)	< 0.001	0.50 (0.40-0.63)	< 0.001
Within stage IV					0.30 (0.13-0.70)	0.005	0.29 (0.09-1.00)	0.050
All-cause mortality
Entire cohort	0.33 (0.28-0.40)	< 0.001	0.37 (0.30-0.47)	< 0.001	0.38 (0.30-0.48)	< 0.001	0.38 (0.30-0.48)	< 0.001
BCLC stage A					NA	NA	NA	NA
BCLC stage B					0.33 (0.23-0.48)	< 0.001	0.30 (0.20-0.44)	< 0.001
BCLC stage C					0.40 (0.30-0.53)	< 0.001	0.41 (0.31-0.54)	< 0.001
BCLC stage D					NA	NA	NA	NA
Liver-cause mortality
Entire cohort	0.32 (0.26-0.39)	< 0.001	0.35 (0.27-0.44)	< 0.001	0.36 (0.28-0.45)	<0 .001	0.35 (0.28-0.45)	< 0.001
BCLC stage A					NA	NA	NA	NA
BCLC stage B					0.32 (0.21-0.47)	< 0.001	0.29 (0.19-0.43)	< 0.001
BCLC stage C					0.37 (0.27-0.49)	< 0.001	0.38 (0.28-0.51)	< 0.001
BCLC stage D					NA	NA	NA	NA

BCLC: Barcelona Clinic Liver Cancer; CI: Confidence interval; HCC: Hepatocellular carcinoma; IPTW: Inverse-probability of treatment weighting; NA: Not applicable; TACE: Transarterial chemoembolization.